Apr 29 (BNP): India is rapidly positioning itself as one of the world’s most accessible destinations for CAR-T cell therapy, driven by advances in biotechnology and more affordable treatment options, according to ImmunoACT.
The company highlighted that India’s growing capabilities in cell and gene therapy are helping make advanced cancer treatments more accessible to patients, both domestically and internationally. CAR-T therapy, which involves modifying a patient’s immune cells to target cancer, is considered a breakthrough in oncology but remains highly expensive in many parts of the world.
Industry experts note that India’s cost advantage, expanding clinical infrastructure, and skilled scientific talent pool are contributing to its emergence as a competitive global centre for advanced therapies. This is also supported by increasing investment in biotech research and stronger collaboration between academia and industry.
ImmunoACT said that India’s progress in this field reflects a broader shift toward innovation-led healthcare solutions that are both effective and affordable. The country is also focusing on scaling up production capabilities and improving regulatory pathways to support faster access to such therapies.
With growing global interest in cost-effective cancer treatment solutions, India is expected to play a more significant role in the future of cell and gene therapy worldwide.
The development marks a key milestone in the country’s journey toward becoming a global hub for advanced medical innovation and accessible healthcare technologies.
